The transcription factor HOXC9 belongs to the homeobox gene family acting as developmental morphogen in several species. HOXC9 is expressed in different vascular beds in vivo. Yet vascular functions of HOXC9 have not been studied.
T he vascular system is the first organ during embryonic development and is mainly formed by 2 processes called vasculogenesis and angiogenesis. 1 A number of important signaling molecules and pathways have been identified in the past 2 decades, such as the vascular endothelial growth factors (VEGFs), ephrins, angiopoietins, netrins, chemokines, and their receptors, regulating different processes of vasculogenesis and angiogenesis. 1 In addition, several upstream transcriptional regulators of these pathways have been identified and functionally characterized. Examples for endothelial-acting transcription factors are Tal1, Gata2, Forkhead, Krüppel-like factor, Ets proteins, Hey genes, Coup-TFII, and Prox1 mediating vascular processes of hematopoietic and endothelial transcription, differentiation, maturation, remodeling, specification, arteriovenous differentiation, and lymphatic patterning. 2 Homeobox genes are characterized by a 61-amino-acidlong homeodomain. These are transcription factors regulating important developmental processes. Beyond their original identification as essential regulators of spatial body development in Drosophila and in other organisms, HOX genes have more recently been recognized as transcription factors regulating physiological and pathophysiological processes in the adult. 3 HOX genes are organized in mice and humans in 4 clusters consisting of 39 different genes. According to sequence homology and genomic position, 13 paralogous groups have been defined. HOX genes regulate gene expression in various developmental processes in higher vertebrates according to 3 basic principles, named spatial collinearity, temporal collinearity, and posterior prevalence. 3 Potential roles of different HOX genes in vascular development and function are poorly studied, and molecular targets of HOX genes in the vasculature are mostly unknown. Yet a number of seminal reports have suggested that different HOX genes regulate various vascular processes, such as vasculogenesis, angiogenesis, vessel maturation, endothelial prolif-eration, and angiogenic activation in tumor angiogenesis. 3, 4 For example, members of the paralogous group 3-eg, HOXA3, 5 HOXB3, 6 and HOXD3 7 -regulate angiogenic functions such as tube formation, capillary morphogenesis, and endothelial cell proliferation, suggesting that paralogous group 3 may positively control angiogenic functions. In turn, members of the paralogous group 5-eg, HOXA5, 8 HOXB5, 9 and also HOXD10 10 -appear to be negative regulators or modifiers of angiogenesis controlling the expression and interaction of important angiogenic molecules, such as angiopoietin-2 and VEGF receptor-2. Last, members of the paralogous group 9 -eg, HOXA9 and HOXC9 -have also been studied in the vasculature. Silencing of HOXA9 expression inhibited endothelial cell migration and tube formation. HoxA9 activates expression of the receptor tyrosine kinase EphB4 and binds the eNOS and VEGF receptor-2 promotor in vitro. 11, 12 HOXC9 is a differentially expressed gene in fetal human smooth muscle cells. It has been suggested that HOXC9 may play a role in specifying the fetal smooth muscle cell phenotype. 13 Recently, HOXC9 has also been shown to be abundantly expressed in CD133 positive cells, 14 in human bone marrow-derived mesenchymal stem cells, 15 and in hindlimb blood vessels. 16 Yet vascular functions of HOXC9 are not established. Together, the data highlight HOXC9 as a very attractive candidate and potential major regulator of endothelial function and angiogenesis.
Interleukin 8 (IL-8; CXCL8) is a chemokine regulating the release of granular enzymes from neutrophils. 17 Besides its function as an inflammation-and infection-regulating cytokine, IL-8 is also involved in the regulation of angiogenesis, tumor progression, and tissue remodeling. 18, 19 Human IL-8 binds to the 2 G-protein coupled receptors CXCR1 and CXCR2 and induces angiogenesis in vitro (eg, by regulating chemotaxis of human umbilical vein endothelial cells [HU-VECs]) and in vivo (eg, by activating angiogenesis in the corneal pocket assay). 20 Gene-targeting studies in mice of IL-8 and its receptors CXCR1 and CXCR2 are hampered by the limited cross-species homology of the corresponding genes. A closely related homolog of human IL-8 does not exist in the mouse genome. 21 Correspondingly, genetargeting studies of the mouse IL-8 receptor (mIL-8Rh; the homolog of human CXCR2) have shown that mIL-8Rh is dispensable during mouse development. Yet, mIL-8Rh-deficient mice display defects in neutrophil migration 22 and delayed wound healing. 23 Interestingly, zebrafish express homologs for human IL-8 and its receptors CXCR1 and CXCR2, 24 which highlights the zebrafish as an attractive model to study IL-8 and its receptors in vivo. Zebrafish CXCL8 (IL-8) is expressed in leukocytes and in intestinal epithelial cells, and its expression is controlled by proinflammatory stimuli. CXCR1 and CXCR2 are robustly expressed in the intermediate cell mass, where vascular and primitive hematopoietic tissues arise, 25 and within the developing gut and head; yet functional gene-silencing experiments in zebrafish have not been reported. 24 Using a combination of several cellular and in vivo experiments, the experiments of this study have identified HOXC9 as a major negative regulator of angiogenesis in vitro and of vascular development in zebrafish by repressing IL-8 functions. In HUVEC, HOXC9 is highly upregulated in resting endothelial cells. It is downregulated during hypoxic episodes, and HOXC9 represses angiogenic activation of endothelial cells. In zebrafish, HOXC9 overexpression inhibits vascular development, and expression silencing of its target gene IL-8 recapitulates a similar vascular phenotype. Therefore, the data identify HOXC9 as an endothelial cell active transcription factor promoting the resting, antiangiogenic endothelial cell phenotype in an IL-8 -dependent manner.
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Methods
Embryos of AB wildtype and the tg(fli1:EGFP) line 26 were raised and staged as described. 27 Embryos were kept in E3 solution at 28.5°C with or without 0.003% 1-phenyl-2-thiourea (Sigma-Aldrich, St. Louis, MO) to suppress pigmentation and staged according to Figure 2A (nϭ3) . B, High efficiency of HUVEC transduction using an AdCherry virus. BFϭbright field. C, Overexpression of HOXC9 in HUVECs inhibited basal and VEGFdriven endothelial migration in the modified Boyden chamber assay. Adeno-HOXC9 transduced HUVECs were allowed to migrate through a membrane for 3 hours using 25 ng/mL VEGF. Migrated cells were stained and counted under the microscope. *PϽ0.05 versus AdGFP; nϭ3 per group. D, Overexpression of HOXC9 in HUVECs inhibited Matrigel tube formation. HUVECs were seeded on Matrigel for 24 hours in presence of 25 ng/mL VEGF, followed by quantification of tube length. The images on the right side show representive data. *PϽ0.05 versus AdGFP; nϭ3 per group. E, Overexpression of HOXC9 in HUVECs inhibited VEGF-induced endothelial proliferation. HUVECs were stimulated with 25 ng/mL VEGF for 72 hours and cell proliferation was assessed by BrdU incorporation. *PϽ0.05 versus AdGFP; nϭ3 per group. F, Adenoviral overexpression of HOXC9 did not induce cell death in HUVECs. HUVECs were seeded in 6 well plates and number of cells was counted at the indicated time points (nϭ3). G, Adenoviral overexpression of HOXC9 did not induce apoptosis in HUVECs as measured by caspase 3/7 activity. As a positive control, apoptosis in AdCherry-transduced HUVECs was induced by staurosporin (nϭ3).
somite number or hours postfertilization (hpf). HUVECs were cultured in endothelial cell growth medium EGM-2 (PromoCell, Heidelburg, Germany) supplemented with 10% heat-inactivated fetal calf serum and antibiotics. The following antibodies were used for this study: mouse anti-HOXC9 [2] (ab50839) (Abcam, Cambridge, UK), goat anti-HOXC9[1] (G-14) (sc-82914, Santa Cruz Biotechnology, Santa Cruz, CA), rabbit anti-chloramphenicol acetyltransferase gene (CAT) (ab50151) (Abcam), goat anti-IL-8 (ab10769) (Abcam), rabbit anti-NFB p65 (sc-109, Santa Cruz Biotechnologies), mouse anti-RNA Polymerase II, clone CTD4H8 (EZ-ChIP Chromatin Immunoprecipitation Kit, Upstate, Temecula, CA), normal mouse IgG (EZ-ChIP Chromatin Immunoprecipitation Kit, Upstate), goat anti-actin (I-19) (Santa Cruz Biotechnology), rabbit anti-GFP (A-11122) (Invitrogen, Carlsbad, CA), Alexa-546 coupled secondary antibodies (molecular probes), and HRP-conjugated antibodies (DAKO, Carpinteria, CA). VEGF was purchased from R&D Systems, and IL-8 (human, recombinant) was purchased from PeproTech (London, UK). Desferrioxamine mesylate and Evans blue were purchased from Sigma-Aldrich.
For details regarding siRNA transfection and viral transduction of HUVECs, hypoxic treatment of HUVECs, Western blot analysis, in vitro angiogenesis assays, 28 measurement of secreted IL-8 via EASIA, chromatin immunoprecipitation, reportergene assay, apo-ptosis assay, reverse transcription polymerase chain reaction (RT-PCR) protocols, DNA-, morpholino-, and intracardial injections, 29 flow cytometry, whole mount antibody staining, and immunohistochemistry, 30 statistical analysis and quantification, and microscopy and analysis, see the Online Supplemental Data at http://circres.ahajournals.org.
Results
HOXC9 Is Abundantly Expressed in Resting Endothelial Cells, Is Downregulated by Hypoxia and Inhibits Endothelial Cell Proliferation, Migration, and Tube Formation in Vitro
HOXC9 has been reported to be expressed in fetal human smooth muscle cells, 13 in CD133 positive cells, 14 in human bone marrow-derived mesenchymal stem 15 cells, and in hind limb blood vessels. 16 Yet it remained unclear whether HOXC9 is expressed in endothelial cells, how HOXC9 expression is regulated in endothelial cells, and whether HOXC9 may exert critical roles in regulating endothelial functions and angiogenesis. First, we analyzed expression of HOXC9 in HUVECs and identified a strong nuclear signal in these cells ( Figure 1A ). The amount of the HOXC9 protein, however, was strongly dependent on endothelial cell monolayer density. In sparse culture (50% confluence), HOXC9 protein was only weakly expressed ( Figure 1B and 1D ). In contrast, confluent and superconfluent HUVEC monolayers expressed strongly upregulated levels of HOXC9. Most abundant expression of HOXC9 was observed in HUVEC spheroids, which represents a 3-dimensional intact quiescent endothelial cell culture in vitro, probably reflecting the best in vitro representation of the quiescent endothelium as it occurs in vivo 31 ( Figure 1B and 1D and Online Figure I) . In contrast, angiogenic activation of endothelial cells using hypoxic conditions strongly inhibited HOXC9 expression in endothelial cells. In fact, HOXC9 expression was downregulated close to the detection limit within 24 hours after hypoxic treatment ( Figure 1C and 1E and Online Figure I ). This process was fully reversible, as evidenced by rising levels of HOXC9 expression following hypoxia withdrawal ( Figure  1C and 1E). Similar data were observed under the hypoxic mimicry desferrioxamine mesylate, revealing reduced levels of HOXC9 in endothelial cells (Online Figures I and II) . Together, the data identify HOXC9 as a cell density-regulated protein that is downregulated in active endothelial cells and on exposure to hypoxic environments. The prominent expression of HOXC9 in quiescent resting endothelial cells consequently suggested a role of HOXC9 in controlling the transition from the resting to the activated endothelial cell phenotype.
In order to examine the role of HOXC9 in controlling the quiescent endothelial cell phenotype, we performed a series of HOXC9 gain-of-function experiments. Adenoviral-driven expression of HOXC9 in HUVECs (Figure 2A , 2B, 2BЈ and Online Figure I) strongly inhibited baseline but not VEGFdriven endothelial cell migration in the modified Boyden chamber assay ( Figure 2C ). Furthermore, tube formation and endothelial cell proliferation in vitro were similarly inhibited in HOXC9 overexpressing HUVECs ( Figure 2D and 2E). To exclude unspecific effects of adenoviral HOXC9-driven expression on cell viability, equal numbers of GFP-or HOXC9transduced HUVECs were seeded, and cell numbers were determined at different time points. Although GFPtransduced HUVECs grew rapidly, growth of HOXC9transduced HUVECs was inhibited, but no signs of apoptosis were observed ( Figure 2F and 2G) . In summary, the data demonstrate that HOXC9 expression exerts a negative growth regulatory effect on endothelial cells and blocks functions related to angiogenesis.
HOXC9 Regulates Endothelial Quiescence and Capillary-like Tube Formation by Regulating Endothelial Cell IL-8
In order to identify HOXC9 target genes in endothelial cells, we performed a transcriptome analysis of HOXC9transduced HUVECs. This screen identified IL-8 as a negatively regulated angiogenic gene yielding an 7.6-fold reduction of IL-8 mRNA expression following adenoviral HOXC9 transduction; yet other important angiogenic molecules were not significantly regulated by HOXC9 (Online Figure III) . Changes in IL-8 mRNA expression were further validated by quantitating IL-8 protein in the supernatant of the different cell populations. EASIA quantitation revealed significantly reduced levels of IL-8 in the supernatants of HOXC9 overexpressing HUVECs ( Figure 3A and Online Figure IV) . Correspondingly, the amount of IL-8 protein was also reduced in the lysate of HOXC9 overexpressing HUVECs ( Figure 3A, box) . In contrast, siRNA-based silencing of HOXC9 resulted in increased levels of IL-8 protein in cell lysates as well as in the supernatant (Figure 3B , 3D, and 3E and Online Figures I and IV) . Interestingly, 56 hours after HOXC9 siRNA transfection, IL-8 levels were not any longer increased ( Figure 3B and Online Figure IV ). This reflects the increased expression of HOXC9 in these settings because it has been observed in confluent and superconfluent endothelial cells ( Figure 1B and 1D ). Finally, we examined IL-8 levels in HUVEC supernatants grown in sparse culture (low confluence) or under confluent conditions (high confluence), because a reduced expression of HOXC9 in sparsely cultured cells ( Figure 1B and 1D) would imply an enhanced secretion of IL-8, and vice versa. Indeed, secretion of IL-8 was strongly reduced in confluent endothelial cells ( Figure 3C and Online Figure IV) , indicating that high expression of HOXC9 in confluent endothelial cells inhibits IL-8 secretion. Moreover, the data also showed that sparse endothelial cells, eg, angiogenic endothelial cells, express high amounts of IL-8 ( Figure  3C and Online Figure IV ). Next, we examined whether the functional consequences of the negative effects of HOXC9 on endothelial cell IL-8 production could be rescued by external IL-8 administration. Endothelial cell migration, endothelial cell proliferation, and Matrigel tube-forming assays with HOXC9 expressing HUVECs were performed toward this end (Figure 4 ). Exogenous IL-8 was able to completely reverse the negative effect of HOXC9 on endothelial cell migration and Matrigel tube formation, confirming IL-8 as the major target of HOXC9-mediated control of angiogenic endothelial cell invasive migration ( Figure 4A and 4B ). Yet, endothelial cell proliferation could not be rescued by exogenous IL-8 administration (data not shown), suggesting the involvement of other, yet unidentified HOXC9 downstream targets in the control of endothelial cell proliferation.
To further validate IL-8 as an HOXC9 downstream target, we performed interleukin-8 reporter assays using different interleukin-8 reporter constructs corresponding to the first Ϫ1481, Ϫ546, Ϫ272, Ϫ185, Ϫ98, or Ϫ8 base pairs (bp) of the IL-8 promoter driving expression of CAT ( Figure 5A and 5B). 32 Coexpression of the single interleukin-8 reporter constructs together with HOXC9 showed a transcriptional repression of interleukin-8 by HOXC9 as evidenced by reduced Figure 5B . Cherry-transduced HeLa cells served as controls and were normalized to 100% (nϭ3). B, Representive Western blot for CAT expression of different IL-8 reporter constructs in presence of HOXC9 or Cherry. Actin served as a loading control. Black line indicates assembled blot. C, Suitability of the HOXC9 antibody [1] for chromatin immunoprecipiation assays as indicated by chromatin immunoprecipitation (ChIP) and Western blot analysis (IB) of HUVEC lysates. D, HUVECs were cross-linked and genomic DNA was fragmented, followed by immunoprecipiation using HOXC9 [1] , NFkB, or control antibodies. HOXC9, NFkB, and control immunoprecipitates were subsequently analyzed by PCR, amplifying parts of the IL-8 promotor. expression of CAT ( Figure 5A and 5B) . Interestingly, HOXC9 inhibited CAT expression in all reporter constructs except for the shortest construct (Ϫ8 bp), which did not show a significant expression under control conditions. 32 This suggested a binding site for HOXC9 within the first Ϫ98 bp of the interleukin-8 promotor. Indeed, sequence analysis of this interleukin-8 promotor region identified a repressor consensus sequence for HOX proteins 33 (Online Figure V) . Last, we performed chromatin-immunoprecipitation 11 assays to examine whether HOXC9 binds directly to the IL-8 promotor. Chromatin immunoprecipitates of HOXC9 ( Figure  5C ) were subsequently analyzed by genomic PCR using specific IL-8 primers amplifying parts of the promotor region of IL-8. Indeed, we identified an IL-8 promotor PCR signal in HOXC9 immunoprecipitates demonstrating a direct interaction of HOXC9 with the IL-8 promotor ( Figure 5D ). A similar approach for NFB, which also binds directly to the IL-8 promotor, 34 was run in parallel as a positive control. Furthermore, an internal assay control using an RNA polymerase II antibody for chromatin immunoprecipitation and a genomic PCR protocol for GAPDH were also included ( Figure 5E ). No genomic PCR signal for IL-8 was identified when using a control antibody instead of the HOXC9 and NFB antibodies for immunoprecipitations ( Figure 5D ). In summary, the experiments show direct binding of HOXC9 to the IL-8 promotor and identified HOXC9 as a major transcriptional repressor of IL-8.
. HOXC9 inhibits CAT expression driven by different IL-8 reporter constructs and binds directly to the IL-8 promotor in HUVECs. A, Different IL-8 reporter constructs driving CAT expression including a quantification (ϮSD) for HOXC9-driven repression of CAT in HeLa cells as shown in
HOXC9 Regulates Vascular Morphogenesis in Zebrafish in an IL-8 -Dependent Manner
The cellular experiments had identified an important role of HOXC9 in regulating angiogenesis-related endothelial cell functions by regulating endothelial cell IL-8 production. In order to validate these data in vivo, we performed HOXC9 gain-of-function experiments in zebrafish aimed at studying HOXC9 during vascular development. HOXC9 was ubiquitously expressed during early embryonic zebrafish development. It was strongly expressed posterior in the neural tube and in the cardinal vein 24 hours postfertilization (hpf) (Online Figure VI) . To study the consequences of vascular HOXC9 overexpression, we pursued endothelial cell-specific HOXC9 overexpression experiments using the flk1 promotor to selectively target endothelial cells ( Figure 6A and 6B) . 35 Injection of the flk1:HOXC9 DNA construct into 1 cell stage of tg(fli1:EGFP) fish embryos resulted in increased endothelial cell HOXC9 expression as evidenced by fluorescence-activated cell sorter analysis and RT-PCR of isolated endothelial cells ( Figure 6C and Online Figure VII) . The analysis of the vasculature at 48 hpf revealed severe defects in the vasculature of endothelial cell HOXC9 overexpressing zebrafish, eg, several intersegmental vessels (ISV) and the dorsal longitudinal anastomotic vessel (DLAV) had not formed properly ( Figure 6A, 6AЈ, 6B, 6BЈ, and 6D) .
The cellular experiments had identified IL-8 as a negatively regulated target of HOXC9. We thus hypothesized that IL-8 silencing in zebrafish may phenocopy the vascular defects seen in endothelial cell HOXC9 overexpressing zebrafish embryos. Silencing of IL-8 expression in zebrafish using 2 independent splice-blocking morpholinos (IL8-SB1-Mo and IL8-SB2-Mo) indeed reproduced the vascular phenotype of endothelial cell HOXC9 gain-of-function experiments in 48 hpf tg(fli1:EGFP) fish embryos ( Figure 7A , 7AЈ, 7B, 7BЈ, 7C, 7CЈ, 7E, 7EЈ, 7F, and 7H). Several ISVs did not form correctly, and the DLAV was partially interrupted in the tg(fli1:EGFP) morphants. To validate the specificity of the IL-8 morpholino experiments, we performed rescue experiments using recombinant IL-8 protein. The IL8-SB1-Mo was injected into the 1-cell stage of tg(fli1:EGFP) fish embryos and at 24 hpf 25 pg IL-8 was injected into the blood circulation, facilitating a cardiac injection ( Figure 7D , 7DЈ, 7F, 7G, and 7GЈ). Indeed, visualization of the vasculature at 48 hpf in the tg(fli1:EGFP) fish embryos showed a normal, developed vasculature in most fish embryos, indicating that cardiac injection of IL-8 was able to rescue the IL-8 morpholino-driven vascular phenotypes ( Figure 7D, 7DЈ, 7F) . To causally link the phenotype of endothelial cell HOXC9 overexpression to downregulated IL-8 production, we next examined whether intravascular IL-8 protein injection in zebrafish embryos would be able to rescue the vascular defects of zebrafish embryos overexpressing HOXC9 in endothelial cells. The flk1:HOXC9 DNA construct was toward this end injected into the 1-cell stage of tg(fli1:EGFP) fish embryos, followed by cardiac IL-8 injection at 24 hpf. Visualization of the vasculature of 48 hpf tg(fli1:EGFP) fish embryos showed normally developed ISV and DLAV in the majority of fish embryos, indicating that external administration of IL-8 was indeed able to rescue the negative effect of HOXC9 on the formation of the vasculature (Figure 8A , 8AЈ, 8B, 8BЈ, 8C, 8CЈ, and 8D). Last, we studied whether the silencing of HOXC9 expression in zebrafish embryos would conversely lead to upregulated IL-8 expression as it had been observed in the cellular experiments ( Figure 3B ). Indeed, silencing of HOXC9 expression in zebrafish embryos using the translational blocking HOXC9 morpholino HOXC9-TB-Mo ( Figure 8F ) led to increased expression of IL-8 in zebrafish morphants at 48 hpf ( Figure 8E ). Interestingly, this did not result in excessive angiogenesis in the HOXC9 morphants (data not shown), indicating that IL-8 on its own was not able to induce ectopic angiogenesis in zebrafish. In conclusion, the data validate HOXC9 as an essential negative regulator of vascular development in zebrafish driven by IL-8.
Discussion
The homeobox gene HOXC9 was identified in this study as an endothelial cell active transcriptional repressor promoting the resting, antiangiogenic endothelial cell phenotype that negatively regulates vascular morphogenesis in an IL-8dependent manner. This conclusion is based on the following Figure VIII) .
Angiogenesis is regulated by a number of angiogenic factors. 1 Among them, VEGF stands out as the primary upstream inducer of the angiogenic cascade. HOXC9 acts as an antiangiogenic transcription factor by repressing IL-8 expression. Yet this does not affect the expression of VEGF and other known angiogenic factors (Online Figure III) . Moreover, HOXC9 does not interfere with VEGF-dependent signaling in endothelial cells. This conclusion is supported by the reduced HOXC9-mediated baseline endothelial cell migration, proliferation, and tube formation and at the same time maintained responsiveness to VEGF-driven angiogenesis. Thus, HOXC9 does not regulate VEGF-driven vascular development, but rather mediates vessel development, endothelial cell quiescence, and pathological angiogenesis independently of VEGF.
The identified HOXC9 target IL-8 is a well-established positive regulator of angiogenesis. 20 Yet mechanistically, the role of IL-8 in regulating angiogenesis is poorly understood. This is largely due to the lack of appropriate murine genetic models, which results from the fact that the mouse genome harbors no closely related homolog to human IL-8. 21 To circumvent these limitations, we used zebrafish as an in vivo model to study the role of IL-8 during developmental angiogenesis and to establish in gain-of-function and loss-offunction experiments the cause and consequence relationship between endothelial HOXC9 expression and IL-8 -mediated regulation of angiogenesis. IL-8 and its receptors CXCR1 and CXCR2 have only recently been described in zebrafish. 24 Morpholino-based gene-silencing studies for IL-8 inhibited vascular development with a largely complementary phenotype resulting from the endothelial cell restricted overexpression of HOXC9. Most definitely, exogenous IL-8 protein was capable of rescuing the angiogenesis defects of HOXC9 overexpressing zebrafish. Thus, the experiments do not just further characterize IL-8 as a regulator of angiogenesis, but more importantly establish a HOXC9/IL-8 axis as critical mediators controlling the switch from the quiescent to the activated endothelial cell phenotype.
IL-8 is only faintly expressed and secreted by quiescent, nonstimulated endothelial cells. Yet on cytokine stimulation, such as by tumor necrosis factor or interleukin-1, IL-8 is transcriptionally activated by AP-1 and NF-B. 36 This implies that expression of IL-8 must be well regulated to prevent an uncontrolled activation. Transcriptional repression of IL-8 can be accomplished by 3 different mechanisms. First, NF-B repression factor NRF binds to the IL-8 promotor and represses its activation; second, binding of the transcription factor octamer-1 to the IL-8 promotor and third, by deacetylation of histone proteins driven by histone deacetylase-1. 36 Our data have now identified a novel mechanism showing that IL-8 repression can also be induced by direct HOXC9 binding to the IL-8 promotor in endothelial cells. This highlights HOXC9 as a major transcriptional repressor of IL-8 in endothelial cells.
In summary, the data of this study have identified a novel transcriptional mechanism of endothelial cell control during vascular development. Because IL-8 is an important regulator of pathological angiogenesis, such as in tumor angiogenesis and in inflammation, and HOXC9 selectively represses angiogenic activation by IL-8, this raises the interesting question of whether a specific activation of HOXC9 may cause inhibition of pathological angiogenesis in vivo. Furthermore, because HOXC9 acts independently of VEGF, HOXC9 repression leading to an increased IL-8 expression may be a contributing mechanism of anti-VEGF resistance during antiangiogenic therapies. 37 
